Company Overview

Waters Corporation provides advanced analytical workflow solutions across Asia, the Americas, and Europe. Founded by James Logan Waters in 1958 and headquartered in Milford, Massachusetts, the company operates through two distinct segments: Waters and TA Instruments. Its core expertise lies in liquid chromatography and mass spectrometry products, which account for nearly 90% of its legacy sales. These technologies are crucial for biopharmaceutical firms, enabling them to analyze molecular structures throughout the complex processes of drug discovery, development, and production. Waters' analytical instruments are recognized as the gold standard in several applications, particularly LC-MS for biopharmaceutical clients, where stringent regulations ensure consistent, long-term recurring sales.

Business Segments and Products

Waters Segment

The primary Waters segment encompasses liquid chromatography instruments, mass spectrometry systems, and precision chemistry consumable products and associated services. The company designs, manufactures, markets, and services both high-performance liquid chromatography (HPLC) and ultra-performance liquid chromatography (UPLC) systems, alongside mass spectrometry (MS) technology. This segment also offers essential support products, including chromatography columns, a range of other consumable supplies, and post-warranty service plans.

TA Instruments Segment

The TA Instruments segment focuses on thermal analysis, rheometry, and calorimetry instrument systems, along with their related service sales. These sophisticated instruments are utilized for predicting the suitability and stability of various materials, including fine chemicals, pharmaceuticals, polymers, metals, and viscous liquids. The applications span across industrial, consumer goods, and healthcare product development, as well as life science research.

Market Position and Applications

Waters Corporation's mass spectrometry (MS) technology is extensively used in drug discovery and development. Its applications include clinical trial testing, detailed analysis of proteins involved in disease processes, nutritional safety assessments, and environmental testing. The company's products serve a diverse clientele, including clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers. These clients leverage Waters' solutions for research and development, quality assurance, and other critical laboratory operations.

In terms of customer segmentation for 2024, biopharmaceutical customers represented 58% of Waters' sales. Industrial clients contributed 31%, and academic/government institutions accounted for 11%. The versatile nature of these tools also extends their utility to food and environmental quality testing, alongside other industrial applications.

Recent Financial Performance

Q2 2025 Results (Ended August 2025)

For the second quarter of 2025, Waters reported sales of $771 million, marking an increase of 9% as reported and 8% in constant currency, compared to $709 million in the second quarter of 2024.

Key financial highlights from Q2 2025 include:

- Non-GAAP EPS: Grew by 12% to $2.95, up from $2.63 in Q2 2024.

- GAAP Diluted EPS: Reported at $2.47, compared to $2.40 in Q2 2024.

- Free Cash Flow: Generated $159 million, with $23 million allocated to capital expenditures.

- Net Debt Position: Stood at $1.1 billion at the close of the quarter.

Updated Guidance for FY 2025

Waters Corporation has revised its full-year sales and earnings guidance upwards. The company now anticipates reported sales growth for fiscal year 2025 to be between 5.0% and 7.0% (net of currency translation). Non-GAAP EPS is projected to be in the range of $12.95 – $13.05.

For the third quarter of 2025, guidance is as follows:

- Third Quarter 2025 Sales Growth: 5% to 7% in constant currency.

- Third Quarter 2025 EPS: Projected between $3.15 and $3.25.

Strategic Acquisition - BD Biosciences & Diagnostic Solutions

Waters Corporation's planned combination with BD Biosciences & Diagnostic Solutions is a significant strategic move designed to accelerate its entry into multiple high-growth adjacent markets. This integration also aims to leverage Waters' proven execution model within resilient, high-volume end markets. The merger, anticipated in early 2026, will substantially reshape the company's market concentrations, increasing its presence in diagnostics (from zero currently) and expanding its footprint in discovery-related life science tools.

The company is strategically positioned to unlock substantial shareholder value through synergies expected to yield immediate impact. Waters plans to achieve synergy targets totaling $290 million post-acquisition.

Growth Drivers and Recent Trends

Waters Corporation's performance is a testament to strong execution across its commercial growth initiatives, rapid adoption of new product offerings, and contributions from emerging growth vectors. The company has seen robust uptake driven by specific market trends such as GLP-1s, PFAS analysis, and the generic drug market.

Significant growth has been observed in its LC and mass spec portfolio. Instruments in these categories grew in the mid-single digits, while recurring revenue increased by 11%. LC-MS systems specifically continued their high single-digit growth trajectory, bolstered by strong replacement activity among large pharmaceutical customers, particularly in the US and Europe. The Alliance iS system, in particular, saw a remarkable year-over-year growth of 300%, making a substantial contribution to this overall expansion.

Waters Corporation continues to solidify its position as a leading provider of analytical instruments and consumables. Its strong market standing in biopharmaceutical quality control, coupled with strategic expansion initiatives into new high-volume markets, positions it for sustained future growth.